QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

Arcutis Biotherapeutics Stock Price, News & Analysis (NASDAQ:ARQT)

$2.24
+0.25 (+12.56%)
(As of 12/4/2023 ET)
Compare
Today's Range
$1.99
$2.28
50-Day Range
$1.84
$5.83
52-Week Range
$1.76
$18.04
Volume
3.96 million shs
Average Volume
1.47 million shs
Market Capitalization
$211.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.67

Arcutis Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
1,224.4% Upside
$29.67 Price Target
Short Interest
Bearish
18.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.95mentions of Arcutis Biotherapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$200,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.78) to ($2.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

126th out of 952 stocks

Pharmaceutical Preparations Industry

43rd out of 434 stocks


ARQT stock logo

About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

ARQT Stock Price History

ARQT Stock News Headlines

Arcutis Biotherapeutics: FDA To Review SNDA For Roflumilast Cream 0.15%
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Arcutis Biotherapeutics Inc Ordinary Shares
FMR LLC Reduces Stake in Arcutis Biotherapeutics Inc
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
What 8 Analyst Ratings Have To Say About Arcutis Biotherapeutics
Earnings Outlook For Arcutis Biotherapeutics
Arcutis to Report Third Quarter 2023 Financial Results
See More Headlines
Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARQT
Fax
N/A
Employees
268
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$29.67
High Stock Price Target
$57.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+1,224.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-311,460,000.00
Net Margins
-546.23%
Pretax Margin
-540.06%

Debt

Sales & Book Value

Annual Sales
$49.04 million
Book Value
$3.44 per share

Miscellaneous

Free Float
74,845,000
Market Cap
$211.42 million
Optionable
Not Optionable
Beta
0.76

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Todd Franklin Watanabe M.A.Mr. Todd Franklin Watanabe M.A. (Age 55)
    President, CEO & Director
    Comp: $1.01M
  • Dr. Bhaskar Chaudhuri Ph.D. (Age 68)
    Co-Founder & Independent Director
    Comp: $59.67k
  • Mr. Masaru Matsuda Esq. (Age 52)
    J.D., Senior VP, General Counsel & Corporate Secretary
    Comp: $626.22k
  • Dr. Patrick E. Burnett M.D. (Age 51)
    Ph.D., Senior VP & Chief Medical Officer
    Comp: $689.95k
  • Mr. John W. Smither CPA (Age 70)
    Interim CFO & Principal Accounting Officer
    Comp: $410.75k
  • Mr. Rajvir Madan
    Chief Digital & Technology Officer
  • Mr. Eric McIntyre
    Head of Investor Relations
  • Ms. Courtney Barton (Age 40)
    VP and Chief Compliance Officer & Privacy Officer
  • Ms. Amanda Sheldon
    Head of Corporate Communications
  • Mr. Corey Padovano
    Vice President of Sales














ARQT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcutis Biotherapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARQT shares.
View ARQT analyst ratings
or view top-rated stocks.

What is Arcutis Biotherapeutics' stock price target for 2024?

9 brokers have issued 12 month price objectives for Arcutis Biotherapeutics' stock. Their ARQT share price targets range from $6.00 to $57.00. On average, they predict the company's share price to reach $29.67 in the next twelve months. This suggests a possible upside of 1,224.4% from the stock's current price.
View analysts price targets for ARQT
or view top-rated stocks among Wall Street analysts.

How have ARQT shares performed in 2023?

Arcutis Biotherapeutics' stock was trading at $14.80 at the beginning of 2023. Since then, ARQT stock has decreased by 84.9% and is now trading at $2.24.
View the best growth stocks for 2023 here
.

When is Arcutis Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ARQT earnings forecast
.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its earnings results on Friday, November, 3rd. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.17. The company earned $38.11 million during the quarter, compared to analysts' expectations of $9.54 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 224.85% and a negative net margin of 546.23%.

What ETF holds Arcutis Biotherapeutics' stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 10,172 shares of ARQT stock, representing 0.89% of its portfolio.

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

(ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager.

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (8.75%), Rubric Capital Management LP (5.33%), Rubric Capital Management LP (5.33%), Jennison Associates LLC (7.19%), Polar Capital Holdings Plc (3.30%) and Northern Trust Corp (0.51%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends
.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ARQT) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -